Targeted Therapy and Immunotherapies in Hepatocellular Carcinoma: Mechanisms and Clinical Studies

Abstract

Liver cancer ranks the second leading cause of cancer-related mortality globally, with a 5-year overall survival rate of about 14.0%. And hepatocellular carcinoma (HCC) constitutes about 80% of it. Given that HCC often remains asymptomatic in its early stages, the diagnosis of the majority of patients occurs at the intermediate or advanced stages, leading to the missed opportunity for surgical resection. Furthermore, the incidence of recurrence after surgical resection for early-stage HCC patients can be as high as 70%. In this context, systemic therapies, including targeted therapies and immunotherapies, have emerged as essential therapeutic strategies for advanced HCC. However, resistance and adverse effects limit their efficacy. This review provides an overview of the molecular signaling pathways underlying HCC and potential mechanisms underlying resistance to systemic therapies and discusses potential therapeutic targets within these pathways. We also examine the clinical outcomes of these systemic therapies, highlighting their efficacy, safety profiles, and the challenges of resistance and toxicity. Finally, we outline future directions for HCC treatment, including combination therapies and personalized treatment strategies, which may offer improved treatment outcomes for individuals with HCC.

Keywords

clinical study / hepatocellular carcinoma / immunotherapy / mechanism / targeted therapy

References

[1] H. Sung, J. Ferlay, R. L. Siegel, et al., “Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries,” CA: A Cancer Journal for Clinicians 71, no. 3 (2021): 209–249.

[2] J. Zheng, J. F. Chou, M. Gönen, et al., “Prediction of Hepatocellular Carcinoma Recurrence beyond Milan Criteria after Resection: Validation of a Clinical Risk Score in an International Cohort,” Annals of Surgery 266, no. 4 (2017): 693–701.

[3] P. Tabrizian, G. Jibara, B. Shrager, M. Schwartz, and S. Roayaie, “Recurrence of Hepatocellular Cancer After Resection: Patterns, Treatments, and Prognosis,” Annals of Surgery 261, no. 5 (2015): 947–955.

[4] R. S. Finn, S. Qin, M. Ikeda, et al., “Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma,” New England Journal of Medicine 382, no. 20 (2020): 1894–1905.

[5] G. K. Abou-Alfa, G. Lau, and M. Kudo, “Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma,” NEJM Evidence 1, no. 8 (2022), EVIDoa2100070.

[6] J. M. Llovet, R. K. Kelley, A. Villanueva, et al., “Hepatocellular Carcinoma,” Nature Reviews Disease Primers 7, no. 1 (2021): 6.

[7] D. Q. Huang, P. Mathurin, H. Cortez-Pinto, and R. Loomba, “Global Epidemiology of Alcohol-Associated Cirrhosis and HCC: Trends, Projections and Risk Factors,” Nature Reviews Gastroenterology & Hepatology 20, no. 1 (2023): 37–49.

[8] D. Q. Huang, H. B. El-Serag, and R. Loomba, “Global Epidemiology of NAFLD-Related HCC: Trends, Predictions, Risk Factors and Prevention,” Nature Reviews Gastroenterology & Hepatology 18, no. 4 (2021): 223–238.

[9] W. Xue, L. Yang, C. Chen, M. Ashrafizadeh, Y. Tian, and R. Sun, “Wnt/β-catenin-driven EMT Regulation in human Cancers,” Cellular and Molecular Life Sciences 81, no. 1 (2024): 79.

[10] Y. Hao, D. Baker, and P. Ten Dijke, “TGF-β-Mediated Epithelial-Mesenchymal Transition and Cancer Metastasis,” International Journal of Molecular Sciences 20, no. 11 (2019): 2767.

[11] H. L. Ang, C. D. Mohan, M. K. Shanmugam, et al., “Mechanism of Epithelial-mesenchymal Transition in Cancer and Its Regulation by Natural Compounds,” Medicinal Research Reviews 43, no. 4 (2023): 1141–1200.

[12] C. Schanbacher, M. E. Goebeler, B. Gerull, and K. Lorenz, “Targeting Pathological ERK1/2 Signaling in Cancer and Beyond,” Trends in Molecular Medicine (2025), https://doi.org/10.1016/j.molmed.2025.08.001.

[13] A. Glaviano, A. S. C. Foo, H. Y. Lam, et al., “PI3K/AKT/mTOR Signaling Transduction Pathway and Targeted Therapies in Cancer,” Molecular Cancer 22, no. 1 (2023): 138.

[14] M. Pibiri and G. Simbula, “Role of the Hippo Pathway in Liver Regeneration and Repair: Recent Advances,” Inflammation and Regeneration 42, no. 1 (2022): 59.

[15] H. Yu, D. Pardoll, and R. Jove, “STATs in Cancer Inflammation and Immunity: A Leading Role for STAT3,” Nature Reviews Cancer 9, no. 11 (2009): 798–809.

[16] Q. Ma, S. Hao, W. Hong, et al., “Versatile Function of NF-ĸB in Inflammation and Cancer,” Experimental Hematology & Oncology 13, no. 1 (2024): 68.

[17] J. Fei and Y. Guo, “MAPK/ERK Signaling in Tumorigenesis: Mechanisms of Growth, Invasion, and Angiogenesis,” EXCLI Journal 24 (2025): 854–879.

[18] D. L. Ou, Y. C. Shen, J. D. Liang, et al., “Induction of Bim Expression Contributes to the Antitumor Synergy Between sorafenib and Mitogen-activated Protein Kinase/Extracellular Signal-regulated Kinase Kinase Inhibitor CI-1040 in Hepatocellular Carcinoma,” Clinical Cancer Research 15, no. 18 (2009): 5820–5828.

[19] J. Rinehart, A. A. Adjei, P. M. Lorusso, et al., “Multicenter Phase II Study of the Oral MEK Inhibitor, CI-1040, in Patients With Advanced Non-small-cell Lung, Breast, Colon, and Pancreatic Cancer,” Journal of Clinical Oncology 22, no. 22 (2004): 4456–4462.

[20] X. Tong, Q. Wang, D. Wu, L. Bao, T. Yin, and H. Chen, “MEK Inhibition by cobimetinib Suppresses Hepatocellular Carcinoma and Angiogenesis in Vitro and in Vivo,” Biochemical and Biophysical Research Communications 523, no. 1 (2020): 147–152.

[21] W. M. Tai, W. P. Yong, C. Lim, et al., “A Phase Ib Study of Selumetinib (AZD6244, ARRY-142886) in Combination With Sorafenib in Advanced Hepatocellular Carcinoma (HCC),” Annals of Oncology 27, no. 12 (2016): 2210–2215.

[22] B. Delire and P. Stärkel, “The Ras/MAPK Pathway and Hepatocarcinoma: Pathogenesis and Therapeutic Implications,” European Journal of Clinical Investigation 45, no. 6 (2015): 609–623.

[23] H. Moon and S. W. Ro, “MAPK/ERK Signaling Pathway in Hepatocellular Carcinoma,” Cancers (Basel) 13, no. 12 (2021): 3026.

[24] L. Zhao, K. Si, S. Luo, L. Zhang, S. Mao, and W. Zhang, “Non-canonical Activation of MAPK Signaling by the lncRNA ASH1L-AS1-encoded Microprotein APPLE Through Inhibition of PP1/PP2A-mediated ERK1/2 Dephosphorylation in Hepatocellular Carcinoma,” Journal of Experimental & Clinical Cancer Research 44, no. 1 (2025): 200.

[25] R. J. Sullivan, J. R. Infante, F. Janku, et al., “First-in-Class ERK1/2 Inhibitor Ulixertinib (BVD-523) in Patients With MAPK Mutant Advanced Solid Tumors: Results of a Phase I Dose-Escalation and Expansion Study,” Cancer Discovery 8, no. 2 (2018): 184–195.

[26] R. Sigaud, L. Rösch, C. Gatzweiler, et al., “The First-in-class ERK Inhibitor ulixertinib Shows Promising Activity in Mitogen-activated Protein Kinase (MAPK)-driven Pediatric Low-grade Glioma Models,” Neuro-Oncology 25, no. 3 (2023): 566–579.

[27] M. A. de Sauvage, C. Torrini, E. Nieblas-Bedolla, et al., “The ERK Inhibitor LY3214996 Augments Anti-PD-1 Immunotherapy in Preclinical Mouse Models of BRAFV600E Melanoma Brain Metastasis,” Neuro-Oncology 26, no. 5 (2024): 889–901.

[28] A. C. Flint, D. K. Mitchell, S. P. Angus, et al., “Combined CDK4/6 and ERK1/2 Inhibition Enhances Antitumor Activity in NF1-Associated Plexiform Neurofibroma,” Clinical Cancer Research 29, no. 17 (2023): 3438–3456.

[29] D. J. Wong, L. Robert, M. S. Atefi, et al., “Antitumor Activity of the ERK Inhibitor SCH772984 [corrected] Against BRAF Mutant, NRAS Mutant and Wild-type Melanoma,” Molecular Cancer 13 (2014): 194.

[30] A. Varga, J. C. Soria, A. Hollebecque, et al., “A First-in-Human Phase I Study to Evaluate the ERK1/2 Inhibitor GDC-0994 in Patients With Advanced Solid Tumors,” Clinical Cancer Research 26, no. 6 (2020): 1229–1236.

[31] Y. Ma, R. Xu, X. Liu, et al., “LY3214996 relieves Acquired Resistance to sorafenib in Hepatocellular Carcinoma Cells,” International Journal of Medical Sciences 18, no. 6 (2021): 1456–1464.

[32] Q. Lin, D. Lei, T. Zhong, et al., “Inactivation of ERK1/2 in Cancer-Associated Hepatic Stellate Cells Suppresses Cancer-stromal Interaction by Regulating Extracellular Matrix in Fibrosis,” American Journal of Cancer Research 14, no. 3 (2024): 1015–1032.

[33] M. C. Mendoza, E. E. Er, and J. Blenis, “The Ras-ERK and PI3K-mTOR Pathways: Cross-talk and Compensation,” Trends in Biochemical Sciences 36, no. 6 (2011): 320–328.

[34] W. J. Jeong, E. J. Ro, and K. Y. Choi, “Interaction Between Wnt/β-catenin and RAS-ERK Pathways and an Anti-cancer Strategy via Degradations of β-catenin and RAS by Targeting the Wnt/β-catenin Pathway,” npj Precision Oncology 2, no. 1 (2018): 5.

[35] E. J. Sun, M. Wankell, P. Palamuthusingam, C. McFarlane, and L. Hebbard, “Targeting the PI3K/Akt/mTOR Pathway in Hepatocellular Carcinoma,” Biomedicines 9, no. 11 (2021): 1639.

[36] G. Hoxhaj and B. D. Manning, “The PI3K-AKT Network at the Interface of Oncogenic Signalling and Cancer Metabolism,” Nature Reviews Cancer 20, no. 2 (2020): 74–88.

[37] I. Ben-Sahra and B. D. Manning, “mTORC1 signaling and the Metabolic Control of Cell Growth,” Current Opinion in Cell Biology 45 (2017): 72–82.

[38] C. Evangelisti, F. Chiarini, F. Paganelli, S. Marmiroli, and A. M. Martelli, “Crosstalks of GSK3 Signaling With the mTOR Network and Effects on Targeted Therapy of Cancer,” Biochimica et Biophysica Acta (BBA) - Molecular Cell Research 1867, no. 4 (2020): 118635.

[39] L. Jiang, L. Li, Y. Liu, et al., “Drug Resistance Mechanism of Kinase Inhibitors in the Treatment of Hepatocellular Carcinoma,” Frontiers in Pharmacology 14 (2023): 1097277.

[40] Q. You, R. Li, J. Yao, et al., “Insights Into Lenvatinib Resistance: Mechanisms, Potential Biomarkers, and Strategies to Enhance Sensitivity,” Medical Oncology 41, no. 3 (2024): 75.

[41] M. J. Matasar, M. Capra, M. Özcan, et al., “Copanlisib plus rituximab versus Placebo plus rituximab in Patients With Relapsed Indolent non-Hodgkin Lymphoma (CHRONOS-3): A Double-Blind, Randomised, Placebo-Controlled, Phase III Trial,” The Lancet Oncology 22, no. 5 (2021): 678–689.

[42] S. Damodaran, F. Zhao, D. A. Deming, et al., “Phase II Study of Copanlisib in Patients with Tumors with PIK3CA Mutations: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1F,” Journal of Clinical Oncology 40, no. 14 (2022): 1552–1561.

[43] A. Patnaik, L. J. Appleman, A. W. Tolcher, et al., “First-in-human Phase I Study of copanlisib (BAY 80–6946), an Intravenous Pan-class I Phosphatidylinositol 3-kinase Inhibitor, in Patients With Advanced Solid Tumors and non-Hodgkin's Lymphomas,” Annals of Oncology 27, no. 10 (2016): 1928–1940.

[44] L. Ye, J. Mayerle, A. Ziesch, F. P. Reiter, A. L. Gerbes, and E. N. De Toni, “The PI3K Inhibitor Copanlisib Synergizes With Sorafenib to Induce Cell Death in Hepatocellular Carcinoma,” Cell Death Discovery 5 (2019): 86.

[45] M. M. Kirstein, A. E. Boukouris, D. Pothiraju, et al., “Activity of the mTOR Inhibitor RAD001, the Dual mTOR and PI3-kinase Inhibitor BEZ235 and the PI3-kinase Inhibitor BKM120 in Hepatocellular Carcinoma,” Liver International 33, no. 5 (2013): 780–793.

[46] D. H. Ahn, J. Li, L. Wei, et al., “Results of an Abbreviated Phase-II Study With the Akt Inhibitor MK-2206 in Patients With Advanced Biliary Cancer,” Scientific Reports 5 (2015): 12122.

[47] E. Benichou, B. Seffou, S. Topçu, et al., “The Transcription Factor ChREBP Orchestrates Liver Carcinogenesis by Coordinating the PI3K/AKT Signaling and Cancer Metabolism,” Nature Communications 15, no. 1 (2024): 1879.

[48] Z. Wang, J. Zhou, J. Fan, et al., “Effect of Rapamycin Alone and in Combination With Sorafenib in an Orthotopic Model of human Hepatocellular Carcinoma,” Clinical Cancer Research 14, no. 16 (2008): 5124–5130.

[49] K. W. Lee, S. H. Kim, K. C. Yoon, et al., “Sirolimus Prolongs Survival After Living Donor Liver Transplantation for Hepatocellular Carcinoma beyond Milan Criteria: A Prospective, Randomised, Open-Label, Multicentre Phase II Trial,” Journal of Clinical Medicine 9, no. 10 (2020): 3264.

[50] D. L. Ou, B. S. Lee, L. I. Lin, et al., “Vertical Blockade of the IGFR- PI3K/Akt/mTOR Pathway for the Treatment of Hepatocellular Carcinoma: The Role of Survivin,” Molecular Cancer 13 (2014): 2.

[51] S. P. Choo, B. Chowbay, Q. S. Ng, et al., “A Phase I Dose-finding and Pharmacodynamic Study of Rapamycin in Combination With Bevacizumab in Patients With Unresectable Hepatocellular Carcinoma,” European Journal of Cancer 49, no. 5 (2013): 999–1008.

[52] R. K. Kelley, N. M. Joseph, H. S. Nimeiri, et al., “Phase II Trial of the Combination of Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma With Tumor Mutation Profiling,” Liver Cancer 10, no. 6 (2021): 561–571.

[53] J. J. Hin Tang, D. K. Hao Thng, J. J. Lim, and T. B. Toh, “JAK/STAT Signaling in Hepatocellular Carcinoma,” Hepatic Oncology 7, no. 1 (2020): Hep18.

[54] Y. Hu, Z. Dong, and K. Liu, “Unraveling the Complexity of STAT3 in Cancer: Molecular Understanding and Drug Discovery,” Journal of Experimental & Clinical Cancer Research 43, no. 1 (2024): 23.

[55] J. R. Grandis, K. A. Skorupski, N. Cheng, et al., “Safety and Efficacy of a STAT3-targeted Cyclic Oligonucleotide: From Murine Models to a Phase II Clinical Trial in Pet Cats With Oral Cancer,” Cancer Cell 43, no. 11 (2025): 2051–2068.e9.

[56] Z. Liu, X. Yu, L. Xu, Y. Li, and C. Zeng, “Current Insight Into the Regulation of PD-L1 in Cancer,” Experimental Hematology & Oncology 11, no. 1 (2022): 44.

[57] M. Caraglia, G. Vitale, M. Marra, A. Budillon, P. Tagliaferri, and A. Abbruzzese, “Alpha-interferon and Its Effects on Signalling Pathways Within Cells,” Current Protein & Peptide Science 5, no. 6 (2004): 475–485.

[58] P. Y. Chu, C. M. Yeh, N. C. Hsu, Y. S. Chang, J. G. Chang, and K. T. Yeh, “Epigenetic Alteration of the SOCS1 Gene in Hepatocellular Carcinoma,” Swiss Medical Weekly: Official Journal of the Swiss Society of Infectious Diseases, the Swiss Society of Internal Medicine, the Swiss Society of Pneumology 140 (2010): w13065.

[59] N. X. Hoan, H. Van Tong, D. P. Giang, et al., “SOCS3 genetic Variants and Promoter Hypermethylation in Patients With Chronic hepatitis B,” Oncotarget 8, no. 10 (2017): 17127–17139.

[60] J. J. Cabrera-Galván, E. Araujo, M. de Mirecki-Garrido, et al., “SOCS2 protects Against Chemical-induced Hepatocellular Carcinoma Progression by Modulating Inflammation and Cell Proliferation in the Liver,” Biomedicine & Pharmacotherapy 157 (2023): 114060.

[61] Z. Dong, B. Dai, R. Wu, et al., “Expression Characteristics, Immune Signature, and Prognostic Value of the SOCS Family Identified by Multiomics Integrative Analysis in Liver Cancer,” Cancer Reports (Hoboken) 7, no. 9 (2024): e2161.

[62] M. G. M. Khan, A. Ghosh, B. Variya, et al., “Prognostic Significance of SOCS1 and SOCS3 Tumor Suppressors and Oncogenic Signaling Pathway Genes in Hepatocellular Carcinoma,” BMC Cancer 20, no. 1 (2020): 774.

[63] G. S. Wilson, A. Tian, L. Hebbard, et al., “Tumoricidal Effects of the JAK Inhibitor Ruxolitinib (INC424) on Hepatocellular Carcinoma in Vitro,” Cancer Letters 341, no. 2 (2013): 224–230.

[64] M. Kusaba, K. Nakao, T. Goto, et al., “Abrogation of Constitutive STAT3 Activity Sensitizes human Hepatoma Cells to TRAIL-mediated Apoptosis,” Journal of Hepatology 47, no. 4 (2007): 546–555.

[65] T. B. Toh, J. J. Lim, L. Hooi, M. Rashid, and E. K. Chow, “Targeting Jak/Stat Pathway as a Therapeutic Strategy Against SP/CD44+ Tumorigenic Cells in Akt/β-catenin-driven Hepatocellular Carcinoma,” Journal of Hepatology 72, no. 1 (2020): 104–118.

[66] A. Troiani, M. Martinez, C. Ward, C. W. Benartzi, D. J. Pinato, and R. Sharma, “Safety and Efficacy of itacitinib, a Selective JAK1 Inhibitor, in Advanced Hepatocellular Cancer: Phase Ib Trial (JAKAL),” Future Oncology 20, no. 36 (2024): 2839–2847.

[67] A. Kawazoe, Y. Kuboki, E. Shinozaki, et al., “Multicenter Phase I/II Trial of Napabucasin and Pembrolizumab in Patients With Metastatic Colorectal Cancer (EPOC1503/SCOOP Trial),” Clinical Cancer Research 26, no. 22 (2020): 5887–5894.

[68] D. J. Jonker, L. Nott, T. Yoshino, et al., “Napabucasin versus Placebo in Refractory Advanced Colorectal Cancer: A Randomised Phase III Trial,” Lancet Gastroenterology and Hepatology 3, no. 4 (2018): 263–270.

[69] Y. Li, Q. Han, H. Zhao, Q. Guo, and J. Zhang, “Napabucasin Reduces Cancer Stem Cell Characteristics in Hepatocellular Carcinoma,” Frontiers in Pharmacology 11 (2020): 597520.

[70] L. Wang, S. Bi, Z. Li, et al., “Napabucasin Deactivates STAT3 and Promotes Mitoxantrone-mediated cGAS-STING Activation for Hepatocellular Carcinoma Chemo-immunotherapy,” Biomaterials 313 (2025): 122766.

[71] Y. Liu, A. Liu, Z. Xu, et al., “XZH-5 Inhibits STAT3 Phosphorylation and Causes Apoptosis in human Hepatocellular Carcinoma Cells,” Apoptosis 16, no. 5 (2011): 502–510.

[72] M. E. Weinblatt, P. Mease, E. Mysler, et al., “The Efficacy and Safety of Subcutaneous Clazakizumab in Patients With Moderate-to-severe Rheumatoid Arthritis and an Inadequate Response to Methotrexate: Results From a Multinational, Phase IIb, Randomized, Double-Blind, Placebo/Active-Controlled, Dose-ranging Study,” Arthritis and Rheumatology 67, no. 10 (2015): 2591–2600.

[73] F. van Rhee, R. S. Wong, N. Munshi, et al., “Siltuximab for Multicentric Castleman's Disease: A Randomised, Double-Blind, Placebo-Controlled Trial,” The Lancet Oncology 15, no. 9 (2014): 966–974.

[74] Y. Wang, X. Miao, Y. Jiang, et al., “The Synergistic Antitumor Effect of IL-6 Neutralization With NVP-BEZ235 in Hepatocellular Carcinoma,” Cell Death & Disease 13, no. 2 (2022): 146.

[75] Z. K. Liu, C. Li, R. Y. Zhang, et al., “EYA2 suppresses the Progression of Hepatocellular Carcinoma via SOCS3-mediated Blockade of JAK/STAT Signaling,” Molecular Cancer 20, no. 1 (2021): 79.

[76] W. Ye, Y. Zhao, Y. Wang, et al., “Farnesoid X Receptor Attenuates the Tumorigenicity of Liver Cancer Stem Cells by Inhibiting STAT3 Phosphorylation,” International Journal of Molecular Sciences 26, no. 3 (2025): 1122.

[77] S. Bernal, I. Prieto, M. Kavanagh, et al., “Development of SOCS1 Mimetics as Novel Approach to Harmonize Inflammation, Oxidative Stress, and Fibrogenesis in Metabolic Dysfunction-Associated Steatotic Liver Disease,” Redox Biology 84 (2025): 103670.

[78] J. M. Lee, J. Yang, P. Newell, et al., “β-Catenin Signaling in Hepatocellular Cancer: Implications in Inflammation, Fibrosis, and Proliferation,” Cancer Letters 343, no. 1 (2014): 90–97.

[79] Y. Tian, M. Zhang, L. X. Liu, et al., “Exploring Non-coding RNA Mechanisms in Hepatocellular Carcinoma: Implications for Therapy and Prognosis,” Frontiers in Immunology 15 (2024): 1400744.

[80] X. Zhang, N. Dong, and X. Hu, “Wnt/β-catenin Signaling Inhibitors,” Current Topics in Medicinal Chemistry 23, no. 10 (2023): 880–896.

[81] M. Ruiz de Galarreta, E. Bresnahan, P. Molina-Sánchez, et al., “β-Catenin Activation Promotes Immune Escape and Resistance to Anti-PD-1 Therapy in Hepatocellular Carcinoma,” Cancer Discovery 9, no. 8 (2019): 1124–1141.

[82] Y. Zhou, J. Xu, H. Luo, X. Meng, M. Chen, and D. Zhu, “Wnt Signaling Pathway in Cancer Immunotherapy,” Cancer Letters 525 (2022): 84–96.

[83] C. H. Khuu, R. M. Barrozo, T. Hai, and S. L. Weinstein, “Activating Transcription Factor 3 (ATF3) Represses the Expression of CCL4 in Murine Macrophages,” Molecular Immunology 44, no. 7 (2007): 1598–1605.

[84] X. Xiao, H. Mo, and K. Tu, “CTNNB1 mutation Suppresses Infiltration of Immune Cells in Hepatocellular Carcinoma Through miRNA-mediated Regulation of Chemokine Expression,” International Immunopharmacology 89, no. Pt A (2020): 107043.

[85] C. Dantzer, J. Vaché, A. Brunel, et al., “Emerging Role of Oncogenic Ss-catenin in Exosome Biogenesis as a Driver of Immune Escape in Hepatocellular Carcinoma,” Elife 13 (2024): RP95191.

[86] J. Calderaro, M. Ziol, V. Paradis, and J. Zucman-Rossi, “Molecular and Histological Correlations in Liver Cancer,” Journal of Hepatology 71, no. 3 (2019): 616–630.

[87] K. Mortezaee, “WNT/β-catenin Regulatory Roles on PD-(L)1 and Immunotherapy Responses,” Clinical and Experimental Medicine 24, no. 1 (2024): 15.

[88] Y. Y. Shao, H. Y. Wang, H. W. Hsu, R. R. Wo, A. L. Cheng, and C. H. Hsu, “Downregulation of PD-L1 Expression by Wnt Pathway Inhibition to Enhance PD-1 Blockade Efficacy in Hepatocellular Carcinoma,” Biology Direct 20, no. 1 (2025): 49.

[89] W. Wang, L. Xu, P. Liu, et al., “Blocking Wnt Secretion Reduces Growth of Hepatocellular Carcinoma Cell Lines Mostly Independent of β-Catenin Signaling,” Neoplasia 18, no. 12 (2016): 711–723.

[90] P. Yeung, L. Beviglia, B. Cancilla, et al., “Abstract 1907: Wnt Pathway Antagonist OMP-54F28 (FZD8-Fc) Inhibits Tumor Growth and Reduces Tumor-initiating Cell Frequency in Patient-derived Hepatocellular Carcinoma and Ovarian Cancer Xenograft Models,” Cancer Research 74, no. 19_Supplement (2014): 1907–1907.

[91] S. Morrone, Z. Cheng, R. T. Moon, F. Cong, and W. Xu, “Crystal Structure of a Tankyrase-Axin Complex and Its Implications for Axin Turnover and Tankyrase Substrate Recruitment,” Proceedings of the National Academy of Sciences of the United States of America 109, no. 5 (2012): 1500–1505.

[92] L. Ma, X. Wang, T. Jia, W. Wei, M. S. Chua, and S. So, “Tankyrase Inhibitors Attenuate WNT/β-catenin Signaling and Inhibit Growth of Hepatocellular Carcinoma Cells,” Oncotarget 6, no. 28 (2015): 25390–25401.

[93] Y. He, D. Liu, A. Ling, et al., “Inhibition of Wnt/β-catenin Increases Anti-tumor Activity by Synergizing With Sorafenib in Hepatocellular Carcinoma,” Cell Death & Disease 16, no. 1 (2025): 466.

[94] J. Li and C. Y. Wang, “TBL1-TBLR1 and Beta-catenin Recruit each Other to Wnt Target-gene Promoter for Transcription Activation and Oncogenesis,” Nature Cell Biology 10, no. 2 (2008): 160–169.

[95] J. Chen, S. Zaidi, S. Rao, et al., “Analysis of Genomes and Transcriptomes of Hepatocellular Carcinomas Identifies Mutations and Gene Expression Changes in the Transforming Growth Factor-β Pathway,” Gastroenterology 154, no. 1 (2018): 195–210.

[96] F. Dituri, S. Mancarella, A. Cigliano, A. Chieti, and G. Giannelli, “TGF-β as Multifaceted Orchestrator in HCC Progression: Signaling, EMT, Immune Microenvironment, and Novel Therapeutic Perspectives,” Seminars in Liver Disease 39, no. 1 (2019): 53–69.

[97] X. Xin, X. Cheng, F. Zeng, Q. Xu, and L. Hou, “The Role of TGF-β/SMAD Signaling in Hepatocellular Carcinoma: From Mechanism to Therapy and Prognosis,” International Journal of Biological Sciences 20, no. 4 (2024): 1436–1451.

[98] R. Derynck and Y. E. Zhang, “Smad-dependent and Smad-independent Pathways in TGF-beta family Signalling,” Nature 425, no. 6958 (2003): 577–584.

[99] Y. Li, W. Fan, F. Link, S. Wang, and S. Dooley, “Transforming Growth Factor β Latency: A Mechanism of Cytokine Storage and Signalling Regulation in Liver Homeostasis and Disease,” JHEP Reports 4, no. 2 (2022): 100397.

[100] Z. J. Chia, H. Kumarapperuma, R. Zhang, P. J. Little, and D. Kamato, “Smad Transcription Factors as Mediators of 7 Transmembrane G Protein-coupled Receptor Signalling,” Acta Pharmacologica Sinica 46, no. 4 (2025): 795–804.

[101] K. Tzavlaki and A. Moustakas, “TGF-β Signaling,” Biomolecules 10, no. 3 (2020): 487.

[102] S. Tu, W. Huang, C. Huang, Z. Luo, and X. Yan, “Contextual Regulation of TGF-β Signaling in Liver Cancer,” Cells 8, no. 10 (2019): 1235.

[103] M. K. Lee, C. Pardoux, M. C. Hall, et al., “TGF-beta Activates Erk MAP Kinase Signalling Through Direct Phosphorylation of ShcA,” Embo Journal 26, no. 17 (2007): 3957–3967.

[104] Y. E. Zhang, “Non-Smad Pathways in TGF-beta Signaling,” Cell Research 19, no. 1 (2009): 128–139.

[105] A. Hamidi, J. Song, N. Thakur, et al., “TGF-β Promotes PI3K-AKT Signaling and Prostate Cancer Cell Migration Through the TRAF6-mediated Ubiquitylation of p85α,” Science Signaling 10, no. 486 (2017): eaal4186.

[106] T. Lin, L. Zeng, Y. Liu, et al., “Rho-ROCK-LIMK-cofilin Pathway Regulates Shear Stress Activation of Sterol Regulatory Element Binding Proteins,” Circulation Research 92, no. 12 (2003): 1296–1304.

[107] F. Li, Q. Jiang, K. J. Shi, H. Luo, Y. Yang, and C. M. Xu, “RhoA Modulates Functional and Physical Interaction Between ROCK1 and Erk1/2 in Selenite-induced Apoptosis of Leukaemia Cells,” Cell Death & Disease 4, no. 7 (2013): e708.

[108] S. Huang, X. Li, W. Gu, et al., “Cytoplasmic Clusterin Suppresses Lung Cancer Metastasis by Inhibiting the ROCK1-ERK Axis,” Cancers (Basel) 14, no. 10 (2022): 2463.

[109] A. Hamidi, V. von Bulow, R. Hamidi, et al., “Polyubiquitination of Transforming Growth Factor β (TGFβ)-Associated Kinase 1 Mediates Nuclear Factor-κB Activation in Response to Different Inflammatory Stimuli,” Journal of Biological Chemistry 287, no. 1 (2012): 123–133.

[110] R. Mao, Y. Fan, Y. Mou, H. Zhang, S. Fu, and J. Yang, “TAK1 lysine 158 Is Required for TGF-β-induced TRAF6-mediated Smad-independent IKK/NF-κB and JNK/AP-1 Activation,” Cell Signalling 23, no. 1 (2011): 222–227.

[111] D. Capece, D. Verzella, I. Flati, P. Arboretto, J. Cornice, and G. Franzoso, “NF-κB: Blending Metabolism, Immunity, and Inflammation,” Trends in Immunology 43, no. 9 (2022): 757–775.

[112] A. O. Giarratana, C. M. Prendergast, M. M. Salvatore, and K. M. Capaccione, “TGF-β Signaling: Critical Nexus of Fibrogenesis and Cancer,” Journal of Translational Medicine 22, no. 1 (2024): 594.

[113] M. Serova, A. Tijeras-Raballand, C. Dos Santos, et al., “Effects of TGF-beta Signalling Inhibition With galunisertib (LY2157299) in Hepatocellular Carcinoma Models and in Ex Vivo Whole Tumor Tissue Samples From Patients,” Oncotarget 6, no. 25 (2015): 21614–21627.

[114] X. He, X. Guo, H. Zhang, X. Kong, F. Yang, and C. Zheng, “Mechanism of Action and Efficacy of LY2109761, a TGF-β Receptor Inhibitor, Targeting Tumor Microenvironment in Liver Cancer After TACE,” Oncotarget 9, no. 1 (2018): 1130–1142.

[115] N. Ungerleider, C. Han, J. Zhang, L. Yao, and T. Wu, “TGFβ Signaling Confers Sorafenib Resistance via Induction of Multiple RTKs in Hepatocellular Carcinoma Cells,” Molecular Carcinogenesis 56, no. 4 (2017): 1302–1311.

[116] J. Chen, W. Feng, M. Sun, et al., “TGF-β1-Induced SOX18 Elevation Promotes Hepatocellular Carcinoma Progression and Metastasis through Transcriptionally Upregulating PD-L1 and CXCL12,” Gastroenterology 167, no. 2 (2024): 264–280.

[117] S. Faivre, A. Santoro, R. K. Kelley, et al., “Novel Transforming Growth Factor Beta Receptor I Kinase Inhibitor Galunisertib (LY2157299) in Advanced Hepatocellular Carcinoma,” Liver International 39, no. 8 (2019): 1468–1477.

[118] M. Ikeda, M. Morimoto, M. Tajimi, et al., “A Phase Ib Study of Transforming Growth Factor-beta Receptor I Inhibitor galunisertib in Combination With sorafenib in Japanese Patients With Unresectable Hepatocellular Carcinoma,” Investigational New Drugs 37, no. 1 (2019): 118–126.

[119] R. K. Kelley, E. Gane, E. Assenat, et al., “A Phase II Study of Galunisertib (TGF-β1 Receptor Type I Inhibitor) and Sorafenib in Patients with Advanced Hepatocellular Carcinoma,” Clinical and Translational Gastroenterology 10, no. 7 (2019): e00056.

[120] B. Zhao, K. Tumaneng, and K. L. Guan, “The Hippo Pathway in Organ Size Control, Tissue Regeneration and Stem Cell Self-renewal,” Nature Cell Biology 13, no. 8 (2011): 877–883.

[121] J. H. Driskill and D. Pan, “Control of Stem Cell Renewal and Fate by YAP and TAZ,” Nature Reviews Molecular Cell Biology 24, no. 12 (2023): 895–911.

[122] Z. Meng, T. Moroishi, and K. L. Guan, “Mechanisms of Hippo Pathway Regulation,” Genes & Development 30, no. 1 (2016): 1–17.

[123] Y. Liu, X. Wang, and Y. Yang, “Hepatic Hippo Signaling Inhibits Development of Hepatocellular Carcinoma,” Clinical and Molecular Hepatology 26, no. 4 (2020): 742–750.

[124] H. Kwon, J. Kim, and E. H. Jho, “Role of the Hippo Pathway and Mechanisms for Controlling Cellular Localization of YAP/TAZ,” Febs Journal 289, no. 19 (2022): 5798–5818.

[125] N. Ghaboura, “Unraveling the Hippo Pathway: YAP/TAZ as central Players in Cancer Metastasis and Drug Resistance,” EXCLI Journal 24 (2025): 612–637.

[126] H. Xiao, N. Jiang, B. Zhou, Q. Liu, and C. Du, “TAZ Regulates Cell Proliferation and Epithelial-mesenchymal Transition of human Hepatocellular Carcinoma,” Cancer Science 106, no. 2 (2015): 151–159.

[127] A. Hooglugt, M. M. van der Stoel, R. A. Boon, and S. Huveneers, “Endothelial YAP/TAZ Signaling in Angiogenesis and Tumor Vasculature,” Frontiers in Oncology 10 (2020): 612802.

[128] D. Liu, Q. Li, Y. Zang, et al., “USP1 modulates Hepatocellular Carcinoma Progression via the Hippo/TAZ Axis,” Cell Death & Disease 14, no. 4 (2023): 264.

[129] X. Li, Q. Liu, S. Xie, X. Wu, and J. Fu, “Mechanism of Action of Cordycepin in the Treatment of Hepatocellular Carcinoma via Regulation of the Hippo Signaling Pathway,” Food Science and Human Wellness 13, no. 2 (2024): 1040–1054.

[130] S. J. Bray and A. Bigas, “Modes of Notch Signalling in Development and Disease,” Nature Reviews Molecular Cell Biology 26, no. 7 (2025): 522–537.

[131] P. Ranganathan, K. L. Weaver, and A. J. Capobianco, “Notch Signalling in Solid Tumours: A Little Bit of Everything but Not all the Time,” Nature Reviews Cancer 11, no. 5 (2011): 338–351.

[132] T. Borggrefe and F. Oswald, “Setting the Stage for Notch: The Drosophila Su(H)-Hairless Repressor Complex,” Plos Biology 14, no. 7 (2016): e1002524.

[133] Q. Huang, J. Li, J. Zheng, and A. Wei, “The Carcinogenic Role of the Notch Signaling Pathway in the Development of Hepatocellular Carcinoma,” Journal of Cancer 10, no. 6 (2019): 1570–1579.

[134] H. Hemati, J. Kaur, R. C. Sobti, and N. Trehanpati, “Inhibition of NOTCH Signaling Pathway Chemosensitizes HCC CD133(+) Cells to Vincristine and 5-fluorouracil Through Upregulation of BBC3,” Biochemical and Biophysical Research Communications 525, no. 4 (2020): 941–947.

[135] A. Montagner, A. Arleo, F. Suzzi, et al., “Notch Signaling and PD-1/PD-L1 Interaction in Hepatocellular Carcinoma: Potentialities of Combined Therapies,” Biomolecules 14, no. 12 (2024): 1581.

[136] P. Andersen, H. Uosaki, L. T. Shenje, and C. Kwon, “Non-canonical Notch Signaling: Emerging Role and Mechanism,” Trends in Cell Biology 22, no. 5 (2012): 257–265.

[137] G. D. Hurlbut, M. W. Kankel, and R. J. Lake, “Artavanis-Tsakonas S. Crossing Paths With Notch in the Hyper-network,” Current Opinion in Cell Biology 19, no. 2 (2007): 166–175.

[138] L. Liu, L. Zhang, S. Zhao, et al., “Non-canonical Notch Signaling Regulates Actin Remodeling in Cell Migration by Activating PI3K/AKT/Cdc42 Pathway,” Frontiers in Pharmacology 10 (2019): 370.

[139] X. Q. Wang, W. Zhang, E. L. Lui, et al., “Notch1-Snail1-E-cadherin Pathway in Metastatic Hepatocellular Carcinoma,” International Journal of Cancer 131, no. 3 (2012): E163–E172.

[140] X. Zhao, B. Sun, D. Sun, et al., “Slug Promotes Hepatocellular Cancer Cell Progression by Increasing sox2 and Nanog Expression,” Oncology Reports 33, no. 1 (2015): 149–156.

[141] L. Zhou, D. S. Wang, Q. J. Li, W. Sun, Y. Zhang, and K. F. Dou, “Downregulation of the Notch Signaling Pathway Inhibits Hepatocellular Carcinoma Cell Invasion by Inactivation of Matrix Metalloproteinase-2 and -9 and Vascular Endothelial Growth Factor,” Oncology Reports 28, no. 3 (2012): 874–882.

[142] R. Qi, H. An, and Y. Yu, “Notch1 signaling Inhibits Growth of human Hepatocellular Carcinoma Through Induction of Cell Cycle Arrest and Apoptosis,” Cancer Research 63, no. 23 (2003): 8323–8329.

[143] P. Viatour, U. Ehmer, L. A. Saddic, et al., “Notch Signaling Inhibits Hepatocellular Carcinoma Following Inactivation of the RB Pathway,” Journal of Experimental Medicine 208, no. 10 (2011): 1963–1976.

[144] C. Giovannini, M. Baglioni, and M. Baron Toaldo, “Notch3 inhibition Enhances Sorafenib Cytotoxic Efficacy by Promoting GSK3b Phosphorylation and p21 Down-regulation in Hepatocellular Carcinoma,” Oncotarget 4, no. 10 (2013): 1618–1631.

[145] B. Zhou, Z. Yan, R. Liu, et al., “Prospective Study of Transcatheter Arterial Chemoembolization (TACE) With Ginsenoside Rg3 versus TACE Alone for the Treatment of Patients With Advanced Hepatocellular Carcinoma,” Radiology 280, no. 2 (2016): 630–639.

[146] M. Lu, Z. Fei, and G. Zhang, “Synergistic Anticancer Activity of 20(S)-Ginsenoside Rg3 and Sorafenib in Hepatocellular Carcinoma by Modulating PTEN/Akt Signaling Pathway,” Biomedicine & Pharmacotherapy 97 (2018): 1282–1288.

[147] C. X. Wu, A. Xu, C. C. Zhang, et al., “Notch Inhibitor PF-03084014 Inhibits Hepatocellular Carcinoma Growth and Metastasis via Suppression of Cancer Stemness due to Reduced Activation of Notch1-Stat3,” Molecular Cancer Therapeutics 16, no. 8 (2017): 1531–1543.

[148] J. Meng, Y. Z. Jiang, S. Zhao, et al., “Tumor-derived Jagged1 Promotes Cancer Progression Through Immune Evasion,” Cell Reports 38, no. 10 (2022): 110492.

[149] T. R. Bürglin, “The Hedgehog Protein family,” Genome Biology 9, no. 11 (2008): 241.

[150] G. Cong, X. Zhu, X. R. Chen, H. Chen, and W. Chong, “Mechanisms and Therapeutic Potential of the Hedgehog Signaling Pathway in Cancer,” Cell Death Discovery 11, no. 1 (2025): 40.

[151] L. Lum and P. A. Beachy, “The Hedgehog Response Network: Sensors, Switches, and Routers,” Science 304, no. 5678 (2004): 1755–1759.

[152] A. N. Sigafoos, B. D. Paradise, and M. E. Fernandez-Zapico, “Hedgehog/GLI Signaling Pathway: Transduction, Regulation, and Implications for Disease,” Cancers (Basel) 13, no. 14 (2021): 3410.

[153] C. M. Della Corte, G. Viscardi, and F. Papaccio, “Implication of the Hedgehog Pathway in Hepatocellular Carcinoma,” World Journal of Gastroenterology 23, no. 24 (2017): 4330–4340.

[154] J. Ding, H. Y. Li, L. Zhang, Y. Zhou, and J. Wu, “Hedgehog Signaling, a Critical Pathway Governing the Development and Progression of Hepatocellular Carcinoma,” Cells 10, no. 1 (2021): 123.

[155] A. Szczepny, S. Rogers, W. S. N. Jayasekara, et al., “The Role of Canonical and Non-canonical Hedgehog Signaling in Tumor Progression in a Mouse Model of Small Cell Lung Cancer,” Oncogene 36, no. 39 (2017): 5544–5550.

[156] Y. Kim, J. W. Yoon, X. Xiao, N. M. Dean, B. P. Monia, and E. G. Marcusson, “Selective Down-regulation of Glioma-Associated Oncogene 2 Inhibits the Proliferation of Hepatocellular Carcinoma Cells,” Cancer Research 67, no. 8 (2007): 3583–3593.

[157] S. Dennler, J. André, I. Alexaki, et al., “Induction of Sonic Hedgehog Mediators by Transforming Growth Factor-beta: Smad3-dependent Activation of Gli2 and Gli1 Expression in Vitro and in Vivo,” Cancer Research 67, no. 14 (2007): 6981–6986.

[158] G. B. Carballo, J. R. Honorato, G. P. F. de Lopes, and T. Spohr, “A Highlight on Sonic Hedgehog Pathway,” Cell Communication and Signaling 16, no. 1 (2018): 11.

[159] A. H. Polizio, P. Chinchilla, X. Chen, D. R. Manning, and N. A. Riobo, “Sonic Hedgehog Activates the GTPases Rac1 and RhoA in a Gli-independent Manner Through Coupling of Smoothened to Gi Proteins,” Science Signaling 4, no. 200 (2011): pt7.

[160] M. Sicurella, M. De Chiara, and L. M. Neri, “Hedgehog and PI3K/Akt/mTOR Signaling Pathways Involvement in Leukemic Malignancies: Crosstalk and Role in Cell Death,” Cells 14, no. 4 (2025): 269.

[161] M. A. Patil, J. Zhang, C. Ho, S. T. Cheung, S. T. Fan, and X. Chen, “Hedgehog Signaling in human Hepatocellular Carcinoma,” Cancer Biology & Therapy 5, no. 1 (2006): 111–117.

[162] J. K. Sicklick, Y. X. Li, A. Jayaraman, et al., “Dysregulation of the Hedgehog Pathway in human Hepatocarcinogenesis,” Carcinogenesis 27, no. 4 (2006): 748–757.

[163] S. Wang, Y. Wang, X. Xun, et al., “Hedgehog Signaling Promotes Sorafenib Resistance in Hepatocellular Carcinoma Patient-derived Organoids,” Journal of Experimental & Clinical Cancer Research 39, no. 1 (2020): 22.

[164] K. Peris, L. Licitra, P. A. Ascierto, et al., “Identifying Locally Advanced Basal Cell Carcinoma Eligible for Treatment With vismodegib: An Expert Panel Consensus,” Future Oncology 11, no. 4 (2015): 703–712.

[165] G. M. Philips, I. S. Chan, M. Swiderska, et al., “Hedgehog Signaling Antagonist Promotes Regression of both Liver Fibrosis and Hepatocellular Carcinoma in a Murine Model of Primary Liver Cancer,” PLoS ONE 6, no. 9 (2011): e23943.

[166] M. Pinter, W. Sieghart, M. Schmid, et al., “Hedgehog Inhibition Reduces Angiogenesis by Downregulation of Tumoral VEGF-A Expression in Hepatocellular Carcinoma,” United European Gastroenterology Journal 1, no. 4 (2013): 265–275.

[167] G. K. Abou-Alfa, L. D. Lewis, P. LoRusso, et al., “Pharmacokinetics and Safety of vismodegib in Patients With Advanced Solid Malignancies and Hepatic Impairment,” Cancer Chemotherapy and Pharmacology 80, no. 1 (2017): 29–36.

[168] K. Harada, R. Ohashi, K. Naito, and K. Kanki, “Hedgehog Signal Inhibitor GANT61 Inhibits the Malignant Behavior of Undifferentiated Hepatocellular Carcinoma Cells by Targeting Non-Canonical GLI Signaling,” International Journal of Molecular Sciences 21, no. 9 (2020): 3126.

[169] L. Lang, “FDA Approves sorafenib for Patients With Inoperable Liver Cancer,” Gastroenterology 134, no. 2 (2008): 379.

[170] S. Wilhelm, C. Carter, M. Lynch, et al., “Discovery and Development of sorafenib: A Multikinase Inhibitor for Treating Cancer,” Nature Reviews Drug Discovery 5, no. 10 (2006): 835–844.

[171] J. M. Llovet, S. Ricci, V. Mazzaferro, et al., “Sorafenib in Advanced Hepatocellular Carcinoma,” New England Journal of Medicine 359, no. 4 (2008): 378–390.

[172] A. L. Cheng, Y. K. Kang, Z. Chen, et al., “Efficacy and Safety of sorafenib in Patients in the Asia-Pacific region With Advanced Hepatocellular Carcinoma: A Phase III Randomised, Double-Blind, Placebo-Controlled Trial,” The Lancet Oncology 10, no. 1 (2009): 25–34.

[173] P. J. Johnson, S. Qin, J. W. Park, et al., “Brivanib versus sorafenib as First-line Therapy in Patients With Unresectable, Advanced Hepatocellular Carcinoma: Results From the Randomized Phase III BRISK-FL Study,” Journal of Clinical Oncology 31, no. 28 (2013): 3517–3524.

[174] A. L. Cheng, Y. K. Kang, D. Y. Lin, et al., “Sunitinib versus sorafenib in Advanced Hepatocellular Cancer: Results of a Randomized Phase III Trial,” Journal of Clinical Oncology 31, no. 32 (2013): 4067–4075.

[175] C. Cainap, S. Qin, W. T. Huang, et al., “Linifanib versus Sorafenib in Patients With Advanced Hepatocellular Carcinoma: Results of a Randomized Phase III Trial,” Journal of Clinical Oncology 33, no. 2 (2015): 172–179.

[176] M. Kudo, R. S. Finn, S. Qin, et al., “Lenvatinib versus sorafenib in First-line Treatment of Patients With Unresectable Hepatocellular Carcinoma: A Randomised Phase III Non-inferiority Trial,” Lancet 391, no. 10126 (2018): 1163–1173.

[177] Z. Peng, W. Fan, and B. Zhu, “Lenvatinib Combined with Transarterial Chemoembolization as First-Line Treatment for Advanced Hepatocellular Carcinoma: A Phase III, Randomized Clinical Trial (LAUNCH),” Journal of Clinical Oncology 41, no. 1 (2023): 117–127.

[178] O. Tohyama, J. Matsui, K. Kodama, et al., “Antitumor Activity of lenvatinib (e7080): An Angiogenesis Inhibitor That Targets Multiple Receptor Tyrosine Kinases in Preclinical human Thyroid Cancer Models,” Journal of Thyroid Research 2014 (2014): 638747.

[179] S. J. Keam and S. Duggan, “Donafenib: First Approval,” Drugs 81, no. 16 (2021): 1915–1920.

[180] S. Qin, F. Bi, S. Gu, et al., “Donafenib versus Sorafenib in First-Line Treatment of Unresectable or Metastatic Hepatocellular Carcinoma: A Randomized, Open-Label, Parallel-Controlled Phase II-III Trial,” Journal of Clinical Oncology 39, no. 27 (2021): 3002–3011.

[181] F. Jing, X. Li, H. Jiang, J. Sun, and Q. Guo, “Combating Drug Resistance in Hepatocellular Carcinoma: No Awareness Today, no Action Tomorrow,” Biomedicine & Pharmacotherapy 167 (2023): 115561.

[182] J. J. G. Marin, R. I. R. Macias, M. J. Monte, et al., “Molecular Bases of Drug Resistance in Hepatocellular Carcinoma,” Cancers (Basel) 12, no. 6 (2020): 1663.

[183] Y. Tao, S. Yin, K. Wei, et al., “SCRN1 confers Hepatocellular Carcinoma Resistance to Ferroptosis by Stabilizing GPX4 via STK38-mediated Phosphorylation,” Nature Cancer 6, no. 12 (2025): 1976–1993.

[184] J. Bruix, W. Y. Tak, A. Gasbarrini, et al., “Regorafenib as Second-line Therapy for Intermediate or Advanced Hepatocellular Carcinoma: Multicentre, Open-label, Phase II Safety Study,” European Journal of Cancer 49, no. 16 (2013): 3412–3419.

[185] J. Bruix, S. Qin, P. Merle, et al., “Regorafenib for Patients With Hepatocellular Carcinoma Who Progressed on sorafenib Treatment (RESORCE): A Randomised, Double-Blind, Placebo-Controlled, Phase III Trial,” Lancet 389, no. 10064 (2017): 56–66.

[186] G. K. Abou-Alfa, T. Meyer, A. L. Cheng, et al., “Cabozantinib in Patients With Advanced and Progressing Hepatocellular Carcinoma,” New England Journal of Medicine 379, no. 1 (2018): 54–63.

[187] T. K. Choueiri, T. Powles, M. Burotto, et al., “Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma,” New England Journal of Medicine 384, no. 9 (2021): 829–841.

[188] S. K. Pal, B. McGregor, C. Suárez, et al., “Cabozantinib in Combination with Atezolizumab for Advanced Renal Cell Carcinoma: Results from the COSMIC-021 Study,” Journal of Clinical Oncology 39, no. 33 (2021): 3725–3736.

[189] R. K. Kelley, L. Rimassa, A. L. Cheng, et al., “Cabozantinib plus atezolizumab versus sorafenib for Advanced Hepatocellular Carcinoma (COSMIC-312): A Multicentre, Open-label, Randomised, Phase III Trial,” The Lancet Oncology 23, no. 8 (2022): 995–1008.

[190] T. Yau, A. Kaseb, A. L. Cheng, et al., “Cabozantinib plus atezolizumab versus Sorafenib for Advanced Hepatocellular Carcinoma (COSMIC-312): Final Results of a Randomised Phase III Study,” Lancet Gastroenterology and Hepatology 9, no. 4 (2024): 310–322.

[191] S. Nagashima, S. Kobayashi, S. Tsunoda, et al., “A Case of Complete Remission by cabozantinib as an End-line Treatment for Advanced Hepatocellular Carcinoma,” Clinical Journal of Gastroenterology 18, no. 1 (2025): 125–129.

[192] S. Qin, Q. Li, S. Gu, et al., “Apatinib as Second-line or Later Therapy in Patients With Advanced Hepatocellular Carcinoma (AHELP): A Multicentre, Double-Blind, Randomised, Placebo-Controlled, Phase III Trial,” Lancet Gastroenterol Hepatology 6, no. 7 (2021): 559–568.

[193] A. X. Zhu, R. S. Finn, M. Mulcahy, et al., “A Phase II and Biomarker Study of ramucirumab, a human Monoclonal Antibody Targeting the VEGF Receptor-2, as First-line Monotherapy in Patients With Advanced Hepatocellular Cancer,” Clinical Cancer Research 19, no. 23 (2013): 6614–6623.

[194] A. X. Zhu, J. O. Park, B. Y. Ryoo, et al., “Ramucirumab versus Placebo as Second-line Treatment in Patients With Advanced Hepatocellular Carcinoma Following First-line Therapy With sorafenib (REACH): A Randomised, Double-Blind, Multicentre, Phase III Trial,” The Lancet Oncology 16, no. 7 (2015): 859–870.

[195] A. X. Zhu, Y. K. Kang, C. J. Yen, et al., “Ramucirumab After sorafenib in Patients With Advanced Hepatocellular Carcinoma and Increased α-fetoprotein Concentrations (REACH-2): A Randomised, Double-Blind, Placebo-Controlled, Phase III Trial,” The Lancet Oncology 20, no. 2 (2019): 282–296.

[196] R. S. Apte, D. S. Chen, and N. Ferrara, “VEGF in Signaling and Disease: Beyond Discovery and Development,” Cell 176, no. 6 (2019): 1248–1264.

[197] V. Ciccone, E. Terzuoli, S. Donnini, A. Giachetti, L. Morbidelli, and M. Ziche, “Correction to: Stemness Marker ALDH1A1 Promotes Tumor Angiogenesis via Retinoic Acid/HIF-1α/VEGF Signalling in MCF-7 Breast Cancer Cells,” Journal of Experimental & Clinical Cancer Research 38, no. 1 (2019): 45.

[198] S. Wang, M. Zhu, Q. Wang, et al., “Alpha-fetoprotein Inhibits Autophagy to Promote Malignant Behaviour in Hepatocellular Carcinoma Cells by Activating PI3K/AKT/mTOR Signalling,” Cell Death & Disease 9, no. 10 (2018): 1027.

[199] H. Kim, M. Jang, and E. Kim, “Exploring the Multifunctional Role of Alpha-Fetoprotein in Cancer Progression: Implications for Targeted Therapy in Hepatocellular Carcinoma and beyond,” International Journal of Molecular Sciences 26, no. 10 (2025): 4863.

[200] A. B. El-Khoueiry, B. Sangro, T. Yau, et al., “Nivolumab in Patients With Advanced Hepatocellular Carcinoma (CheckMate 040): An Open-label, Non-comparative, Phase I/II Dose Escalation and Expansion Trial,” Lancet 389, no. 10088 (2017): 2492–2502.

[201] T. Yau, J. W. Park, R. S. Finn, et al., “Nivolumab versus sorafenib in Advanced Hepatocellular Carcinoma (CheckMate 459): A Randomised, Multicentre, Open-label, Phase III Trial,” The Lancet Oncology 23, no. 1 (2022): 77–90.

[202] S. Qin, Z. Ren, Z. Meng, et al., “Camrelizumab in Patients With Previously Treated Advanced Hepatocellular Carcinoma: A Multicentre, Open-label, Parallel-group, Randomised, Phase II Trial,” The Lancet Oncology 21, no. 4 (2020): 571–580.

[203] Z. Ren, M. Ducreux, G. K. Abou-Alfa, et al., “Tislelizumab in Patients With Previously Treated Advanced Hepatocellular Carcinoma (RATIONALE-208): A Multicenter, Non-Randomized, Open-Label, Phase II Trial,” Liver Cancer 12, no. 1 (2023): 72–84.

[204] S. Qin, M. Kudo, T. Meyer, et al., “Tislelizumab vs Sorafenib as First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Phase III Randomized Clinical Trial,” JAMA Oncology 9, no. 12 (2023): 1651–1659.

[205] A. X. Zhu, R. S. Finn, and J. Edeline, “Pembrolizumab in Patients With Advanced Hepatocellular Carcinoma Previously Treated With sorafenib (KEYNOTE-224): A Non-randomised, Open-label Phase II Trial,” The Lancet Oncology 19, no. 7 (2018): 940–952.

[206] R. S. Finn, B. Y. Ryoo, P. Merle, et al., “Pembrolizumab as Second-Line Therapy in Patients with Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial,” Journal of Clinical Oncology 38, no. 3 (2020): 193–202.

[207] S. Qin, Z. Chen, W. Fang, et al., “Pembrolizumab versus Placebo as Second-Line Therapy in Patients from Asia with Advanced Hepatocellular Carcinoma: A Randomized, Double-Blind, Phase III Trial,” Journal of Clinical Oncology 41, no. 7 (2023): 1434–1443.

[208] L. Rimassa, S. L. Chan, B. Sangro, et al., “Five-year Overall Survival Update From the HIMALAYA Study of Tremelimumab plus Durvalumab in Unresectable HCC,” Journal of Hepatology 83, no. 4 (2025): 899–908.

[209] T. Yau, P. R. Galle, T. Decaens, et al., “Nivolumab plus ipilimumab versus lenvatinib or sorafenib as First-line Treatment for Unresectable Hepatocellular Carcinoma (CheckMate 9DW): An Open-label, Randomised, Phase III Trial,” Lancet 405, no. 10492 (2025): 1851–1864.

[210] X. Gao, N. Xu, Z. Li, et al., “Safety and Antitumour Activity of cadonilimab, an Anti-PD-1/CTLA-4 Bispecific Antibody, for Patients With Advanced Solid Tumours (COMPASSION-03): A Multicentre, Open-label, Phase Ib/2 Trial,” The Lancet Oncology 24, no. 10 (2023): 1134–1146.

[211] Q. Qiao, C. Han, S. Ye, et al., “The Efficacy and Safety of cadonilimab Combined With lenvatinib for First-line Treatment of Advanced Hepatocellular Carcinoma (COMPASSION-08): A Phase Ib/II Single-arm Clinical Trial,” Frontiers in Immunology 14 (2023): 1238667.

[212] Y. Wang, S. Pan, J. Tian, et al., “Cadonilimab, a PD-1/CTLA-4 Bispecific Antibody in Unresectable Hepatocellular Carcinoma: A Real-world Study,” Cancer Immunology, Immunotherapy 74, no. 6 (2025): 186.

[213] Y. Huang, Y. Yang, Y. Zhao, et al., “QL1706 (anti-PD-1 IgG4/CTLA-4 antibody) plus Chemotherapy With or Without bevacizumab in Advanced Non-small Cell Lung Cancer: A Multi-cohort, Phase II Study,” Signal Transduction and Targeted Therapy 9, no. 1 (2024): 23.

[214] X. Wang, Y. Wu, J. Huang, D. Zong, and X. He, “Bispecific Antibodies (PD-1/CTLA-4) vs. PD-1 Inhibitors With Platinum-based Chemotherapy±Bevacizumab as First-line Therapy for Persistent, Recurrent, or Metastatic Cervical Cancer: A Retrospective Matched Cohort Study,” Cancer Immunology, Immunotherapy 74, no. 11 (2025): 347.

[215] Y. Zhao, Y. Ma, A. Zang, et al., “First-in-human Phase I/Ib Study of QL1706 (PSB205), a Bifunctional PD1/CTLA4 Dual Blocker, in Patients With Advanced Solid Tumors,” Journal of Hematology & Oncology 16, no. 1 (2023): 50.

[216] S. Qin, J. Fan, and F. Yang, “LBA38 Iparomlimab and tuvonralimab (QL1706) With Bevacizumab and/or Chemotherapy in First-line (1L) Treatment of Advanced Hepatocellular Carcinoma (aHCC): A Randomized, Open-label, Phase II/III Study (DUBHE-H-308),” Annals of Oncology 35 (2024): S1229–S1230.

[217] A. B. Siegel, E. I. Cohen, A. Ocean, et al., “Phase II Trial Evaluating the Clinical and Biologic Effects of bevacizumab in Unresectable Hepatocellular Carcinoma,” Journal of Clinical Oncology 26, no. 18 (2008): 2992–2998.

[218] S. Qin, M. Chen, A. L. Cheng, et al., “Atezolizumab plus Bevacizumab versus Active Surveillance in Patients With Resected or Ablated High-risk Hepatocellular Carcinoma (IMbrave050): A Randomised, Open-label, Multicentre, Phase III Trial,” Lancet 402, no. 10415 (2023): 1835–1847.

[219] Z. Ren, J. Xu, Y. Bai, et al., “Sintilimab plus a Bevacizumab Biosimilar (IBI305) versus Sorafenib in Unresectable Hepatocellular Carcinoma (ORIENT-32): A Randomised, Open-label, Phase II–III Study,” The Lancet Oncology 22, no. 7 (2021): 977–990.

[220] Y. Shi, G. Han, J. Zhou, et al., “Toripalimab plus bevacizumab versus sorafenib as First-line Treatment for Advanced Hepatocellular Carcinoma (HEPATORCH): A Randomised, Open-label, Phase III Trial,” Lancet Gastroenterology and Hepatology 10, no. 7 (2025): 658–670.

[221] C. Zhao, Y. Zhang, G. Wang, et al., “Finotonlimab (PD-1 inhibitor) plus bevacizumab (bevacizumab biosimilar) as First-tier Therapy for Late-stage Hepatocellular Carcinoma: A Randomized Phase II/III Trial,” Signal Transduction and Targeted Therapy 10, no. 1 (2025): 249.

[222] B. Sangro, M. Kudo, J. P. Erinjeri, et al., “Durvalumab With or Without Bevacizumab With Transarterial Chemoembolisation in Hepatocellular Carcinoma (EMERALD-1): A Multiregional, Randomised, Double-Blind, Placebo-Controlled, Phase III Study,” Lancet 405, no. 10474 (2025): 216–232.

[223] S. Qin, S. L. Chan, S. Gu, et al., “Camrelizumab plus rivoceranib versus sorafenib as First-line Therapy for Unresectable Hepatocellular Carcinoma (CARES-310): A Randomised, Open-label, International Phase III Study,” Lancet 402, no. 10408 (2023): 1133–1146.

[224] A. Vogel, S. L. Chan, Z. G. Ren, et al., “Camrelizumab plus rivoceranib vs sorafenib as First-line Therapy for Unresectable Hepatocellular Carcinoma (uHCC): Final Overall Survival Analysis of the Phase III CARES-310 Study,” Journal of Clinical Oncology 42, no. 16 (2024): 4110.

[225] K. G. Kuonqui, A. C. Campbell, B. L. Pollack, et al., “Regulation of VEGFR3 Signaling in Lymphatic Endothelial Cells,” Frontiers in Cell and Developmental Biology 13 (2025): 1527971.

[226] S. M. Z. Bokhari and P. Hamar, “Vascular Endothelial Growth Factor-D (VEGF-D): An Angiogenesis Bypass in Malignant Tumors,” International Journal of Molecular Sciences 24, no. 17 (2023): 13317.

[227] K. Kuonqui, A. C. Campbell, A. Sarker, et al., “Dysregulation of Lymphatic Endothelial VEGFR3 Signaling in Disease,” Cells 13, no. 1 (2023): 68.

[228] Y. Sun, A. Zhou, W. Zhang, et al., “Anlotinib in the Treatment of Advanced Hepatocellular Carcinoma: An Open-label Phase II Study (ALTER-0802 study),” Hepatology International 15, no. 3 (2021): 621–629.

[229] Y. Zheng, A. R. A. Mislang, J. Coward, et al., “Penpulimab, an Anti-PD1 IgG1 Antibody in the Treatment of Advanced or Metastatic Upper Gastrointestinal Cancers,” Cancer Immunology, Immunotherapy 71, no. 10 (2022): 2371–2379.

[230] C. Han, S. Ye, C. Hu, et al., “Clinical Activity and Safety of Penpulimab (Anti-PD-1) with Anlotinib as First-Line Therapy for Unresectable Hepatocellular Carcinoma: An Open-Label, Multicenter, Phase Ib/II Trial (AK105-203),” Frontiers in Oncology 11 (2021): 684867.

[231] J. Zhou, L. Bai, J. Luo, et al., “Anlotinib plus penpulimab versus sorafenib in the First-line Treatment of Unresectable Hepatocellular Carcinoma (APOLLO): A Randomised, Controlled, Phase III Trial,” The Lancet Oncology 26, no. 6 (2025): 719–731.

[232] R. S. Finn, M. Ikeda, A. X. Zhu, et al., “Phase Ib Study of Lenvatinib plus Pembrolizumab in Patients with Unresectable Hepatocellular Carcinoma,” Journal of Clinical Oncology 38, no. 26 (2020): 2960–2970.

[233] J. M. Llovet, M. Kudo, P. Merle, et al., “Lenvatinib plus pembrolizumab versus lenvatinib plus Placebo for Advanced Hepatocellular Carcinoma (LEAP-002): A Randomised, Double-Blind, Phase III Trial,” The Lancet Oncology 24, no. 12 (2023): 1399–1410.

[234] M. Kudo, Z. Ren, Y. Guo, et al., “Transarterial Chemoembolisation Combined With lenvatinib plus pembrolizumab versus Dual Placebo for Unresectable, Non-metastatic Hepatocellular Carcinoma (LEAP-012): A Multicentre, Randomised, Double-Blind, Phase III Study,” Lancet 405, no. 10474 (2025): 203–215.

[235] Y. Chen, J. Zhang, W. Hu, et al., “Envafolimab plus Lenvatinib and Transcatheter Arterial Chemoembolization for Unresectable Hepatocellular Carcinoma: A Prospective, Single-arm, Phase II Study,” Signal Transduction and Targeted Therapy 9, no. 1 (2024): 280.

[236] H. D. Kim, S. Jung, H. Y. Lim, et al., “Regorafenib plus nivolumab in Unresectable Hepatocellular Carcinoma: The Phase II RENOBATE Trial,” Nature Medicine 30, no. 3 (2024): 699–707.

RIGHTS & PERMISSIONS

2026 The Author(s). MedComm published by Sichuan International Medical Exchange & Promotion Association (SCIMEA) and John Wiley & Sons Australia, Ltd.